BioLife Solutions (NASDAQ:BLFS) Posts Earnings Results, Beats Estimates By $0.07 EPS

Market Beat
2025.05.12 22:38
portai
I'm PortAI, I can summarize articles.

BioLife Solutions (NASDAQ:BLFS) reported quarterly earnings of $0.04 per share, surpassing estimates of ($0.03) by $0.07. Despite a negative net margin of 38.98% and a negative return on equity of 6.61%, the stock rose 3.9% to $23.24. Analysts have set a consensus price target of $31.17, with HC Wainwright raising their target from $27.00 to $30.00. Insider selling was noted, with executives reducing their holdings. BioLife Solutions specializes in bioproduction tools for the cell and gene therapy industry.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) posted its earnings results on Thursday. The medical equipment provider reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07, Zacks reports. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. BioLife Solutions updated its FY 2025 guidance to EPS.

Get BioLife Solutions alerts:

BioLife Solutions Stock Up 3.9 %

  • Best Biotech Stocks to Invest in Now

Shares of BLFS traded up $0.88 during midday trading on Friday, hitting $23.24. The company had a trading volume of 1,161,730 shares, compared to its average volume of 385,880. BioLife Solutions has a 1 year low of $17.70 and a 1 year high of $29.55. The firm has a market capitalization of $1.10 billion, a P/E ratio of -21.92 and a beta of 2.01. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company's 50-day simple moving average is $23.84 and its 200-day simple moving average is $25.27.

Analysts Set New Price Targets

Several research firms recently issued reports on BLFS. HC Wainwright increased their target price on BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. StockNews.com lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $31.17.

  • 3 Small-Cap Medical Stocks Moving Markets Today

View Our Latest Stock Analysis on BioLife Solutions

Insider Buying and Selling

In other news, EVP Aby J. Mathew sold 10,589 shares of the company's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $239,946.74. Following the completion of the transaction, the executive vice president now directly owns 309,576 shares of the company's stock, valued at approximately $7,014,992.16. This represents a 3.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Troy Wichterman sold 25,687 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total value of $582,067.42. Following the completion of the transaction, the chief financial officer now owns 189,242 shares in the company, valued at approximately $4,288,223.72. The trade was a 11.95 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,127 shares of company stock worth $1,676,533. Company insiders own 2.20% of the company's stock.

BioLife Solutions Company Profile

(Get Free Report)

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

See Also

  • Five stocks we like better than BioLife Solutions
  • How to Use the MarketBeat Stock Screener
  • GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
  • When to Sell a Stock for Profit or Loss
  • Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock
  • How to invest in marijuana stocks in 7 steps
  • Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in BioLife Solutions Right Now?

Before you consider BioLife Solutions, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.

While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.